We are a purpose-driven team, passionate about developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders, beginning with postpartum depression (PPD), adjustment disorder (AjD) and generalized anxiety disorder (GAD). Leveraging our team’s extensive experience in neuroscience drug development, we are advancing luvesilocin, a patented, clinical-stage drug candidate designed as a safe, fast-acting, short duration therapy for patients with underserved mental health disorders. Luvesilocin, the only 4-OH-DiPT prodrug in clinical development, achieved its primary endpoint and demonstrated clinically meaningful benefit in the REKINDLE Phase 2 clinical trial as a potential treatment for PPD. Based on these data, luvesilocin was granted Breakthrough Therapy Designation (BTD) for PPD by the U.S. Food and Drug Administration (FDA), and Reunion plans to advance into a single pivotal Phase 3 trial in 2026. Additionally, Reunion is advancing the REKINDLE Phase 2 clinical trial evaluating luvesilocin as a potential treatment for AjD in cancer and other medical illnesses and the RECLAIM Phase 2 clinical evaluating luvesilocin as a potential treatment of GAD. Data from REKINDLE are expected in the first quarter of 2027 and data from RECLAIM are expected in the second quarter of 2027.

ADVOCACY PARTNERS

Reunion Neuroscience is proud to partner with leading advocacy groups to build awareness of maternal mental health and drive increased support for pregnant and postpartum women.